- Investing Ideas
- /
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Nanjing King-Friend Biochemical PharmaceuticalLtd
Market Cap: CN¥16.4b
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
603707
CN¥10.16
7D
1.2%
1Y
-34.2%
Jiangsu Sinopep-Allsino Biopharmaceutical
Market Cap: CN¥12.0b
A biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China.
688076
CN¥37.91
7D
-2.5%
1Y
1.0%